Efficacy, Equivalence, and Operability of Trelegy 100 Ellipta in patients with COPD and ACO

Efficacy and Operability of Trelegy 100 Ellipta in patients with COPD and ACO - Effects of Trelegy in patients with COPD and ACO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041409

Enrollment

Registered

2020-08-14

Start date

2020-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD and Asthma and COPD overlap (ACO)

Interventions

Trelegy 100 Ellipta onece daily, 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with COPD complicated with asthmatic conditions and ACO who require three drugs: ICS, LABA, and LAMA.

Exclusion criteria

Exclusion criteria: The exclusion criteria were as follows: age <40 years; inability to inhale unassisted; inability to perform spirometry tests; pregnancy; severe comorbidities affecting quality of life, including malignancy, cardiac failure, renal failure, or severe liver dysfunction; and comorbidity of severe prostatic hypertrophy and closed-angle glaucoma.

Design outcomes

Primary

Measure	Time frame
Efficacy (QoL) and safety after 8 weeks	—

Secondary

Measure	Time frame
Respiratory functions after 8 weeks	—

Countries

Japan

Contacts

Public ContactMasato Muraki

Kindai University Nara Hospital Department of Respiratory Medicine and Allergology

muraki-m@med.kindai.ac.jp0743-77-0880

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026